Sweden-based Bonesupport has obtained CE mark approval for its Cerament|V, an injectable vancomycin eluting bone substitute developed to promote and protect bone healing in the management of osteomyelitis.

Cerament|V is an injectable and resorbable bone graft substitute, which has been developed to fill bone gaps and voids and can augment hardware and bone fractures during surgical procedures. It can remodel into healthy native bone within six to 12 months.

The bone graft substitute can prevent colonization of sensitive microorganisms and protect the bone healing, specifically in challenging cases of deep bone infection.

Bonesupport CEO Lloyd Diamond said: "Expanding our portfolio of drug-delivery therapeutics is an important part of our growth strategy and we are proud to be executing on that with the launch of Cerament|V.

"As a pioneer of antibiotic eluting bone substitute technology, the launch of Cerament|V marks the first ever injectable bone substitute with two drugs, vancomycin and Iohexol, to receive approval."

The new product is an extension to the firm’s antibiotic eluting bone substitute portfolio that includes Cerament|G, claimed to be the first injectable gentamicin eluting bone substitute.

Vancomycin is said to be used to treat gram-positive bacteria, which are resistant to most antibiotics, including Methicillin-resistant Staphylococcus aureus (MRSA).